Ms. Amy W. Schulman is Executive Vice President, General Counsel, Business Unit Lead Consumer Healthcare of Pfizer Inc. She was Executive Vice President and General Counsel since December 2010 and Business Unit Lead, Consumer Healthcare for Pfizer since August 2012. Executive Vice President and General Counsel; President and General Manager, Nutrition from December 2010 until November 2012. Senior Vice President and General Counsel from June 2008 until December 2010. Ms. Schulman was a partner at the law firm of DLA Piper from 1997 until joining Pfizer in June 2008. Currently a Director of Zoetis and Chair of the Zoetis Corporationrationrate Governance Committee, Member of the Board of Directors of Wesleyan University and the Brooklyn Academy of Music.
Executive VP, Bus. Unit Lead of Consumer Healthcare and General Counsel
Age: 51 EVP Since 2012
The company has Return on Asset of 6.22 % which means that on every $100 spent on asset it made $6.22 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 12.68 % implying that it generated $12.68 on every 100 dollars invested.
The company has 40.4 B in debt with debt to equity (D/E) ratio of 0.49 which is OK given its current industry classification. Pfizer Inc has Current Ratio of 2.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.
Entity SummaryPfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer Inc [PFE] is traded on New York Stock Exchange in USA. It is located in New York, NY and employs 89,400 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| PFE NYSE
Pfizer Inc has less than 29.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Pfizer price boundaries
Promote Pfizer and Amy Schulman